Augusto Villanueva
#162,202
Most Influential Person Now
Researcher
Augusto Villanueva's AcademicInfluence.com Rankings
Augusto Villanuevacomputer-science Degrees
Computer Science
#9422
World Rank
#9896
Historical Rank
Machine Learning
#4118
World Rank
#4167
Historical Rank
Artificial Intelligence
#4460
World Rank
#4521
Historical Rank
Database
#6387
World Rank
#6620
Historical Rank
Download Badge
Computer Science
Augusto Villanueva's Degrees
- Masters Computer Science Stanford University
- Bachelors Computer Engineering University of California, Berkeley
Similar Degrees You Can Earn
Why Is Augusto Villanueva Influential?
(Suggest an Edit or Addition)Augusto Villanueva's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Hepatocellular carcinoma (1998) (1293)
- Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling (2008) (1266)
- Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets (2015) (1253)
- Gene expression in fixed tissues and outcome in hepatocellular carcinoma. (2008) (1158)
- Hepatocellular Carcinoma. (2019) (978)
- Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. (2009) (900)
- Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. (2015) (885)
- Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis. (2017) (718)
- Pivotal role of mTOR signaling in hepatocellular carcinoma. (2008) (675)
- Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. (2008) (566)
- Genomics and signaling pathways in hepatocellular carcinoma. (2007) (553)
- Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. (2017) (545)
- Advances in targeted therapies for hepatocellular carcinoma in the genomic era (2015) (430)
- Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. (2013) (418)
- A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. (2006) (381)
- Tumour evolution in hepatocellular carcinoma (2019) (379)
- Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. (2011) (378)
- Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. (2009) (320)
- DNA methylation‐based prognosis and epidrivers in hepatocellular carcinoma (2015) (304)
- Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. (2010) (299)
- Medical therapies for hepatocellular carcinoma: a critical view of the evidence (2013) (299)
- A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. (2013) (288)
- β-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma. (2019) (287)
- Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. (2012) (270)
- UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma. (2014) (242)
- Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. (2010) (235)
- Targeted therapies for hepatocellular carcinoma. (2011) (231)
- IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. (2010) (228)
- Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. (2009) (227)
- MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. (2011) (223)
- Experimental models of hepatocellular carcinoma. (2008) (210)
- Genetic profiling of hepatocellular carcinoma using next-generation sequencing. (2016) (195)
- A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma (2009) (195)
- Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. (2013) (185)
- Cancer gene discovery in hepatocellular carcinoma. (2010) (183)
- Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. (2012) (182)
- Intratumoral heterogeneity and clonal evolution in liver cancer (2020) (178)
- Emerging Signaling Pathways in Hepatocellular Carcinoma (2012) (177)
- Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference (2020) (164)
- Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial (2018) (160)
- Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. (2016) (150)
- Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma (2015) (147)
- Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib (2012) (143)
- Pathogenesis of hepatocellular carcinoma and molecular therapies (2009) (141)
- New Strategies in Hepatocellular Carcinoma: Genomic Prognostic Markers (2010) (135)
- Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival. (2019) (132)
- Gene-expression signature of vascular invasion in hepatocellular carcinoma. (2011) (115)
- Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. (2012) (115)
- Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. (2020) (113)
- Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity. (2017) (112)
- Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma. (2017) (105)
- Advances in targeted therapies for hepatocellular carcinoma in the genomic era (2015) (105)
- Liver cancer in 2013: Mutational landscape of HCC—the end of the beginning (2014) (104)
- Unique genomic profile of fibrolamellar hepatocellular carcinoma. (2015) (104)
- Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. (2008) (103)
- A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection (2015) (101)
- Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib (2012) (94)
- Erratum for Advances in targeted therapies for hepatocellular carcinoma in the genomic era. [Nat Rev Clin Oncol. 2015] (2015) (92)
- IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models. (2016) (87)
- Biomarkers for Hepatobiliary Cancers (2020) (86)
- VEGF signaling in cancer treatment. (2014) (83)
- A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma (2018) (81)
- Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma. (2019) (75)
- Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps (2008) (72)
- Intratumor Molecular and Phenotypic Diversity in Hepatocellular Carcinoma (2015) (70)
- DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival (2014) (69)
- Liver cancer: Effect of HCV clearance with direct-acting antiviral agents on HCC (2016) (68)
- A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration (2014) (64)
- Gene signatures in the management of hepatocellular carcinoma. (2012) (64)
- High-density single cell mRNA sequencing to characterize circulating tumor cells in hepatocellular carcinoma (2018) (61)
- Evidence-based management of HCC: Systematic review and meta-analysis of randomized controlled trials (2002-2020). (2021) (60)
- Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma (2020) (60)
- Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR (2013) (59)
- Liquid biopsy in the clinical management of hepatocellular carcinoma (2020) (56)
- Mitohormesis Primes Tumor Invasion and Metastasis (2019) (55)
- Signaling Pathways in Hepatocellular Carcinoma (2011) (51)
- International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. (2021) (51)
- Depicting the role of TP53 in hepatocellular carcinoma progression. (2011) (49)
- Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials (2019) (49)
- Liquid biopsy in liver cancer. (2015) (48)
- Carcinogen‐induced hepatic tumors in KLF6+/− mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation (2011) (43)
- The future of patient-derived tumor xenografts in cancer treatment. (2015) (42)
- Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing (2012) (40)
- Molecular profiling to predict hepatocellular carcinoma outcome (2009) (38)
- Management of small hepatocellular carcinoma in cirrhosis: focus on portal hypertension. (2013) (35)
- Molecular pathogenesis and systemic therapies for hepatocellular carcinoma (2022) (35)
- Molecular targeted therapies in hepatocellular carcinoma: from pre-clinical models to clinical trials. (2008) (33)
- Why men are at higher risk for hepatocellular carcinoma? (2012) (33)
- The oncogenic role of hepatitis delta virus in hepatocellular carcinoma (2019) (32)
- Molecular pathogenesis of hepatocellular carcinoma. (2011) (31)
- Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification (2022) (30)
- Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma. (2021) (28)
- Accuracy of plasma levels of polymorphonuclear elastase as early prognostic marker of acute pancreatitis in routine clinical conditions (2006) (27)
- The transition from inflammation to cancer in the liver (2016) (26)
- Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis (2021) (25)
- DNA Methylation Profiling of Human Hepatocarcinogenesis (2020) (23)
- Unannotated small RNA clusters associated with circulating extracellular vesicles detect early stage liver cancer (2021) (22)
- Safety of percutaneous ethanol injection as neoadjuvant therapy for hepatocellular carcinoma in waiting list liver transplant candidates. (2005) (22)
- Hepatocellular Carcinoma. Reply. (2019) (20)
- Lymphotoxins: new targets for hepatocellular carcinoma. (2009) (19)
- Impact of intra‐individual molecular heterogeneity in personalized treatment of hepatocellular carcinoma (2012) (19)
- The Role of Liquid Biopsy in Hepatocellular Carcinoma Prognostication (2021) (19)
- Rethinking future development of molecular therapies in hepatocellular carcinoma: a bottom-up approach. (2013) (19)
- Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma (2020) (19)
- Inherited hepatocellular carcinoma. (2010) (18)
- Mannose Phosphate Isomerase and Mannose Regulate Hepatic Stellate Cell Activation and Fibrosis in Zebrafish and Humans (2019) (18)
- Natural history of nonalcoholic steatohepatitis/nonalcoholic fatty liver disease‐hepatocellular carcinoma: Magnitude of the problem from a hepatology clinic perspective (2016) (18)
- Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications (2022) (18)
- Hypomethylation in HBV integration regions aids non-invasive surveillance to hepatocellular carcinoma by low-pass genome-wide bisulfite sequencing (2020) (18)
- Neoadjuvant therapies for hepatocellular carcinoma before liver transplantation: A critical appraisal (2006) (17)
- miRNA delivery: emerging therapy for hepatocellular carcinoma. (2010) (17)
- Parity predisposes breasts to the oncogenic action of PAPP-A and activation of the collagen receptor DDR2 (2019) (17)
- Mechanisms of Action of Drugs Effective in Hepatocellular Carcinoma (2019) (15)
- Signaling pathways in hepatocellular carcinoma. (2021) (12)
- Role of circulating tumor DNA to help decision-making in hepatocellular carcinoma (2018) (11)
- Signaling in hepatocellular carcinoma (2015) (10)
- Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology (2019) (10)
- Divergent evolutionary trajectories in transplanted tumor models (2017) (9)
- microRNAs: new ways to block tumor angiogenesis? (2012) (9)
- Liver capsule: Molecular‐based signatures in hepatocellular carcinoma (2016) (8)
- Transcriptomic characterization of cancer-testis antigens identifies MAGEA3 as a driver of tumor progression in hepatocellular carcinoma (2021) (8)
- Molecular epidemiology in HCV-related hepatocellular carcinoma: first steps. (2012) (7)
- Molecular profiling of liver cancer heterogeneity. (2017) (7)
- A phenotypical map of disseminated hepatocellular carcinoma suggests clonal constraints in metastatic sites (2019) (6)
- Abstract LB-233: IGF activation in a molecular subclass of hepatocellular carcinoma and preclinical efficacy of IGF-1R blockage (2010) (6)
- Circulating tumor cells and cholangiocarcinoma (2016) (6)
- Tumor fitness, immune exhaustion and clinical outcomes: impact of immune checkpoint inhibitors (2019) (6)
- Clinical Trial Watch: Reports from the Liver Meeting®, AASLD, San Francisco, November 2015. (2016) (5)
- [Genomic prognostic markers in hepatocellular carcinoma]. (2012) (5)
- Clinical Trial Watch: Reports from the EASL International Liver Congress (ILC), Vienna, April 2015. (2015) (5)
- Experimental Models of Liquid Biopsy in Hepatocellular Carcinoma Reveal Clone‐Dependent Release of Circulating Tumor DNA (2021) (5)
- Hepatocellular carcinoma enters the sequencing era. (2011) (5)
- Molecular Oncology: Hepatocellular carcinoma (2013) (5)
- Progress towards molecular patient stratification of hepatocellular carcinoma: Lost in translation? (2017) (5)
- Landscape of oncoviral genotype and co-infection via human papilloma and hepatitis B viral tumor in situ profiling (2021) (4)
- Non-invasive imaging criteria for the diagnosis of hepatocellular carcinoma in non-cirrhotic patients with chronic hepatitis B (2021) (4)
- Correction: Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma. (2019) (3)
- The usual SASPects of liver cancer (2015) (3)
- Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials (2019) (3)
- [Cell biology and genetics in liver cancer]. (2007) (3)
- Digital-resolution and highly sensitive detection of multiple exosomal small RNAs by DNA toehold probe-based photonic resonator absorption microscopy. (2022) (3)
- Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma. (2012) (3)
- Current management of liver cancer (2007) (3)
- The Impact of Translational Research in Hepatology (2019) (3)
- MS.liverK: an R package for transcriptome-based computation of molecular subtypes and functional signatures in liver cancer (2019) (3)
- Tumor Heterogeneity and Resistance to Targeted Therapies in Hepatocellular Carcinoma (2017) (3)
- Nontumor Prognostic Factors in Hepatocellular Carcinoma (2016) (2)
- Diagnostic and Prognostic Performance of Liquid Biopsy in Hepatocellular Carcinoma (2017) (2)
- Biomarker Development Using Liquid Biopsy in Hepatocellular Carcinoma. (2022) (2)
- Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma (2021) (2)
- Abstract 2996: Overexpression of potential oncogenic microRNAs defines a new molecular subclass of hepatocellular carcinoma (2010) (2)
- Unannotated small RNA clusters in circulating extracellular vesicles detect early stage liver cancer (2020) (2)
- Abstract 2936: Molecular characterization of the immune subclass of hepatocellualr carcinoma (2017) (1)
- Genetically engineered mouse models: future tools to predict clinical trial results in oncology? (2013) (1)
- Hepatocellular carcinoma in Mongolia delineates unique molecular traits and a mutational signature associated with environmental agents. (2022) (1)
- Resistance to Molecular Therapies for Hepatocellular Carcinoma (2017) (1)
- Activation of Ras/MAPK and mTOR pathways in hepatocellular carcinoma: Tumor growth inhibition with Ras/mTOR pathway abrogation by a novel combination of Sorafenib and rapamycin (2007) (1)
- Genomic tracing of the elusive liver cancer ancestor. (2010) (1)
- Landscape of oncoviral genotype and co-infection via Human papilloma and Hepatitis B viral tumor in-situ profiling (2020) (1)
- Trunk events present minimal intra-and inter-tumoral heterogeneity in hepatocellular carcinoma (2017) (1)
- Novel non-protein biomarkers for early detection of hepatocellular carcinoma (2021) (1)
- Emerging Tools for Hepatocellular Carcinoma Surveillance. (2022) (1)
- Dysregulation of hedgehog pathway signaling in hepatocellular carcinoma (2006) (1)
- Discriminatory Changes in Circulating Metabolites as a Predictor of Hepatocellular Cancer in Patients with Metabolic (Dysfunction) Associated Fatty Liver Disease (2022) (1)
- Transplantation for hepatocellular carcinoma—worth waiting for? (2014) (1)
- Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials (2022) (1)
- Molecular characterization of hepatocellular carcinoma in Mongolia delineates unique genomic features (2020) (0)
- International Liver cancer Association (ILCA) White Paper on Hepatocellular carcinoma Risk Stratification and Surveillance. (2023) (0)
- Signaling Pathways and Rationale for Molecular Therapies in Hepatocellular Carcinoma (2009) (0)
- Regeneration linked miRNA modify tumor phenotype and can enforce multi-lineage growth arrest in vivo (2021) (0)
- Contents Vol. 8, 2019 (2019) (0)
- Mutations in circulating tumor DNA predict primary resistance to systemic therapies in patients with advanced hepatocellular carcinoma (2020) (0)
- Abstract 2388: Molecular heterogeneity and trunk driver mutations in hepatocellular carcinoma (2016) (0)
- Selected summary for the 2015 Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE). (2016) (0)
- G05 : Exome sequencing of 243 liver tumors identifies new mutational signatures and potential therapeutic targets (2015) (0)
- Intra-tumoral epigenetic heterogeneity and aberrant molecular clocks in hepatocellular carcinoma (2021) (0)
- Abstract 2973: Exome sequencing of 243 liver tumors identifies new mutational signatures and potential therapeutic targets (2015) (0)
- Efficacy and safety of the ultrasonography-guided percutaneous ethanol injection as adjuvant therapy of hepatocellular carcinoma on waiting list for liver transplantation (2003) (0)
- Abstract 3944: Characterization of molecular heterogeneity in hepatocellular carcinoma: Trunk and branch drivers (2017) (0)
- CLINICAL — LIVER A Hepatocellular Carcinoma 5-Gene Score Associated With Survival of Patients After Liver Resection (2013) (0)
- Subject Index Vol. 81, Suppl. 1, 2011 (2011) (0)
- Single-cell mRNA sequencing to characterize circulating tumor cells in hepatocellular carcinoma (2018) (0)
- Abstract 2410: Characterization of Notch as an oncogenic driver in liver (2011) (0)
- High-density single cell mRNA sequencing to characterize circulating tumor cells in hepatocellular carcinoma (2018) (0)
- Abstract 4718: Potent preclinical antitumor effects induced by pan-histone deacetylase inhibitor panobinostat in combination with sorafenib in hepatocellular carcinoma (2012) (0)
- Abstract 3820: Epigenetic re-expression of fetal IGF2 as therapeutic target in hepatocellular carcinoma (2016) (0)
- Prognostic and predictive factors in patients treated with ramucirumab (RAM) with advanced hepatocellular carcinoma (aHCC) and elevated alpha-fetoprotein (AFP): Results from two phase III trials. (2021) (0)
- DYSREGULATION OF TUMOR SUPPRESSOR KLF6 INCREASES HCC RELATED MORTALITY IN HCV INFECTED PATIENTS AND INCIDENCE OF TUMOR IN MOUSE MODEL OF HEPATIC CARCINOGENESIS (2009) (0)
- Reprogramming necroptosis limits immune responses and prevents liver cancer development (2022) (0)
- 155. Tumor Necrosis In Vivo Caused by a Novel Combination of Sorafenib and Rapamycin: Targeting the RAS and Motor Pathways ION Hepatocellular Carcinoma (2008) (0)
- Abstract 3415: Tumor fitness and immune exhaustion: Checkpoint vs endogenous settings (2019) (0)
- Abstract 1387: The importance of FGF pathway in hepatocellular carcinoma and its role in acquired resistance to anti-angiogenic therapies (2012) (0)
- Abstract 1507: Regional DNA methylation profiling reveals novel epigenetic intra-tumoral heterogeneity signatures and aberrant molecular clocks in hepatocellular carcinoma (2020) (0)
- Abstract 2383: Multiregional RNA sequencing identifies intratumor transcriptomic heterogeneity in a subset of early-stage hepatocellular carcinoma (2016) (0)
- Contents Vol. 7, 2018 (2018) (0)
- TITLE : IGF 2 is up-regulated by epigenetic mechanisms in hepatocellular 1 carcinoma and is an actionable oncogene in experimental models (2016) (0)
- Tumor fitness, immune exhaustion and clinical outcomes: impact of immune checkpoint inhibitors (2020) (0)
- Abstract 1189: Deciphering the impact of immune editing on liver cancer clonal evolution using immunogenomics (2018) (0)
- 34INHEPATOCELLULAR CARCINOMA (HCC). (2014) (0)
- Expanding the TMA Method to Investigate Phylogenetic Relationships Between Primary and Metastatic Hepatocellular Carcinoma (2018) (0)
- Extracellular vesicles for early detection of hepatocellular carcinoma (2021) (0)
- Abstract 4393: Integrative molecular analysis of gene expression and methylation reveals 116 putative key regulator genes of human hepatocarcinogenesis (2017) (0)
- Intratumoral heterogeneity and clonal evolution in liver cancer (2020) (0)
- Abstract B071: Validating sequence similarity-driven neoepitope fitness models via immunogenomics on TCGA and multiregional tumor data (2019) (0)
- Liver Cancer (2019) (0)
- Refining the immune class of hepatocellular carcinoma (2020) (0)
- Clinical course of irritable bowel syndrome (IBS): A 2–3 years follow-up study (2001) (0)
- Abstract #444: Molecular and clinical characterization of RICTOR (MTORC2) as a candidate oncogene in hepatocellular carcinoma (2009) (0)
- P0221 : Acquired resistance to sorafenib in hepatocellular carcinoma is mediated by tumor initiating cells (cancer stem cells) (2015) (0)
- HCC-CCA: Hepatocellular cholangiocarcinoma HCC: Hepatocellular Carcinoma iCCA: Intrahepatic Cholangiocarcinoma WHO: World Health Organization CLC: Cholangiolocellular Carcinoma TGF-beta: Transforming Growth Factor, Beta 1 TERT: Telomerase Reverse Transcriptase KRAS: Kirsten Rat Sarcoma Viral Oncogen (2017) (0)
- Abstract 474: Genome-wide DNA methylation profiling reveals novel candidate epigenetic gatekeepers in hepatocarcinogenesis (2019) (0)
- afety of Percutaneous Ethanol Injection as Neoadjuvant herapy for Hepatocellular Carcinoma in Waiting List iver Transplant Candidates (0)
- Abstract 2130: Human papillomavirus and hepatitis B virus in situ tumor oncoviral genotype and coinfection drive oncogenesis and patient clinical response in cross cancer analysis (2020) (0)
- Abstract 402: RNA-sequencing of plasma exosomes reveals specific transcriptomic profiles in patients with hepatocellular carcinoma (2019) (0)
- A potential role of cancer testis antigens in hepatocellular carcinoma progression (2017) (0)
- Abstract 4618: Integrative molecular classification of extrahepatic cholangiocarcinoma (2018) (0)
- Parity predisposes breasts to the oncogenic action of PAPP-A and activation of the collagen receptor DDR2 (2019) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Augusto Villanueva?
Augusto Villanueva is affiliated with the following schools:
